DayTwo, the microbiome human discovery platform that offers a glycemic control solution for people with type 2 diabetes, announced $31 Million in Series B financing. DayTwo will use the funding to accelerate go-to-market initiatives in […]
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, announced a direct investment of $10 million from Taiho Ventures, LLC to fund the discovery […]
OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned […]
DermBiont, a clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has closed an $8M Series A. The funding round was led by Zola […]
Intralytix, Inc., announced today that is has entered into a joint collaboration agreement with the Eliava Foundation and Ferring Pharmaceuticals to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine […]
The Food and Drug Administration (FDA) issued an Important Safety Alert regarding the use of FMT and risk of serious adverse reactions due to transmission of Multi-Drug Resistant Organisms. The Alert was issued after two immunocompromised adults […]
Chemicals produced by healthy bacteria could be used to assess the health of the gut microbiome and help identify critically-ill children at greatest risk of organ failure, a study published in Critical Care Medicine has […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of […]
Speakers: Thomas Tompkins, R&D Manager & Ghania Sohail, Clinical Research Associate – Rosell Institute for Microbiome & Probiotics by Lallemand
BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced it has licensed a new set of bacterial targets from JSR Corporation, for the development and commercialization of phage therapies for […]
The gut microbiome is a complex, interconnected ecosystem of species. And, like any ecosystem, some organisms are predators and some are prey. A new study led by investigators at Brigham and Women’s Hospital and the […]